Adamax vs Exenatide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Adamax is a synthetic neuropeptide related to brain-derived neurotrophic factor (BDNF) signaling pathways. It is explored for cognitive enhancement, neuroprotection, and mood support, with proposed mechanisms involving TrkB receptor activation and enhancement of neuroplasticity similar to endogenous BDNF.
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Half-Life
- Estimated 1-3 hours (short; peptide degradation)
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Admin Route
- Subcutaneous, Intranasal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 200-400 mcg per dose
- 5 mcg, titrate to 10 mcg
- Frequency
- Once daily or every other day
- Twice daily
- Key Benefits
- Proposed enhancement of learning and memory consolidation
- Neuroprotective via BDNF-TrkB pathway support
- May improve mood and resilience to stress
- Potential support for neurogenesis
- Cognitive clarity and focus enhancement (reported anecdotally)
- Explored for neurodegeneration and age-related cognitive decline
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Side Effects
- Limited human safety data; largely anecdotal reports
- Possible headache or mild overstimulation
- Sleep disruption with late-day dosing
- Unknown long-term safety profile
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Stacks With
- —
- —